What is Quest Diagnostics?
Diagnostic information services company with $11.04B 2025 revenue scale and public-market buying capacity.
- Category
- Diagnostic information services
- Headquarters
- Secaucus, NJ
- Founded
- 1967
- Employees
- 55,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: DGX; Public company
What is Quest Diagnostics?
Quest Diagnostics is a public diagnostic information services company headquartered in Secaucus, NJ. Quest Diagnostics reported full-year 2025 revenues of $11.04 billion, up 11.8% from 2024, and Q4 2025 revenue of $2.81 billion.
Quest Diagnostics operates in diagnostic information services with a portfolio that includes Clinical lab testing, Advanced diagnostics, Employer and health-plan testing, Quanum. Quest Diagnostics reported full-year 2025 revenues of $11.04 billion, up 11.8% from 2024, and Q4 2025 revenue of $2.81 billion. The company employs about 55,000+ and trades as NYSE: DGX, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Quest Diagnostics through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Quest Diagnostics is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Quest Diagnostics offer?
Quest Diagnostics offers products and services across Clinical lab testing, Advanced diagnostics, Employer and health-plan testing, Quanum and related healthcare workflows.
- Clinical lab testing· Diagnostics
- Advanced diagnostics· Specialty testing
- Employer and health-plan testing· Services
- Quanum· Healthcare IT
- Patient service centers· Access network
- Molecular and genetic testing· Specialty diagnostics
How does Quest Diagnostics make money?
Quest Diagnostics earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Quest Diagnostics earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $11.04B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Quest Diagnostics improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Quest Diagnostics?
Quest Diagnostics is led by Jim Davis, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Jim DavisChairman, Chief Executive Officer and PresidentCEO since 2022Leads diagnostic information services, health-system partnerships, and advanced diagnostics.
- Sam SamadExecutive Vice President and Chief Financial OfficerCFO since 2022Oversees finance, M&A, and capital allocation.
- Cecilia McKenneySenior Vice President and Chief Human Resources OfficerSenior executiveLeads people strategy across a large distributed workforce.
- Catherine T. DohertySenior Vice President, Regional BusinessesBusiness leaderLeads regional diagnostic operations.
How do you contact Quest Diagnostics's leadership?
Quest Diagnostics publishes official Quest investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Quest investor-relations contact route; personal executive email format not verified- Jim DavisChairman, Chief Executive Officer and Presidentofficial Quest investor-relations contact route
- Sam SamadExecutive Vice President and Chief Financial Officerofficial Quest investor-relations contact route
- Cecilia McKenneySenior Vice President and Chief Human Resources Officerofficial Quest investor-relations contact route
How much funding has Quest Diagnostics raised?
Quest Diagnostics is a mature public company, not a venture-backed startup. It trades as NYSE: DGX and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Quest Diagnostics's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is NYSE: DGX, $11.04B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Quest Diagnostics has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Quest Diagnostics get here?
Quest Diagnostics grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1967MetPath foundedQuest traces roots to Metropolitan Pathology Laboratory.
- 1997Quest Diagnostics createdCorning spins off its lab business as Quest Diagnostics.
- 2000sNational lab network scalesQuest grows through acquisitions and managed-care contracts.
- 2024LifeLabs acquisitionQuest expands in Canada through the LifeLabs acquisition.
- 2025$11.04B revenueQuest reports full-year 2025 revenue of $11.04 billion.
- 2026Guidance raisedQuest raises 2026 revenue and EPS guidance after Q1 results.
Who are Quest Diagnostics's competitors?
Quest Diagnostics competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- LabcorpCompetes directly in national clinical labs, patient service centers, and health-plan contracts.
- Exact SciencesCompetes in advanced cancer diagnostics and screening pathways.
- Sonic HealthcareCompetes in laboratory services and pathology networks.
- ARUP LaboratoriesCompetes in esoteric and reference laboratory services.
- Mayo Clinic LaboratoriesCompetes in reference testing and specialized diagnostics.
- BioReferenceCompetes in clinical labs, specialty testing, and regional accounts.
Quest Diagnostics — frequently asked questions
